CGON (STOCKS)
CG Oncology, Inc. Common stock
$67.700000
+0.000000 (+0.00%)
Prev close: $67.700000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Arthur Kuan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,714.57M
- Employees
- 113
- P/E (TTM)
- -32.51
- P/B (TTM)
- 7.26
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
15
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.53 | $-0.63 | +0.0967 | +15.43% |
|
Sep 2025 (Q3)
|
$-0.57 | $-0.57 | +0.0012 | +0.21% |
|
Jun 2025 (Q2)
|
$-0.54 | $-0.47 | -0.0717 | -15.31% |
|
Mar 2025 (Q1)
|
$-0.45 | $-0.41 | -0.0386 | -9.38% |
Financial Statements
| Revenues | $4.04M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $194.81M |
| Nonoperating Income/Loss | $29.78M |
| Operating Expenses | $194.81M |
| Research and Development | $116.64M |
| Other Operating Expenses | $78.17M |
| Operating Income/Loss | -$190.77M |
| Income/Loss From Continuing Operations After Tax | -$161.00M |
| Income/Loss From Continuing Operations Before Tax | $4.04M |
| Income Tax Expense/Benefit | -$270.00K |
| Income Tax Expense/Benefit, Current | $8.00K |
| Income Tax Expense/Benefit, Deferred | -$278.00K |
| Net Income/Loss | -$161.00M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$161.00M |
| Net Income/Loss Available To Common Stockholders, Basic | -$161.00M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.08 |
| Diluted Earnings Per Share | -$2.08 |
| Basic Average Shares | 77,303,440 |
| Diluted Average Shares | 77,303,440 |
| Assets | $791.59M |
| Current Assets | $759.48M |
| Accounts Receivable | $688.00K |
| Inventory | $1.57M |
| Other Current Assets | $757.22M |
| Noncurrent Assets | $32.12M |
| Fixed Assets | $15.60M |
| Other Non-current Assets | $16.52M |
| Liabilities | $38.99M |
| Current Liabilities | $30.84M |
| Accounts Payable | $5.71M |
| Other Current Liabilities | $25.12M |
| Noncurrent Liabilities | $8.15M |
| Equity | $752.60M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $752.60M |
| Liabilities And Equity | $791.59M |
| Net Cash Flow From Operating Activities | -$132.35M |
| Net Cash Flow From Operating Activities, Continuing | -$132.35M |
| Net Cash Flow From Investing Activities | -$245.82M |
| Net Cash Flow From Investing Activities, Continuing | -$245.82M |
| Net Cash Flow From Financing Activities | $153.59M |
| Net Cash Flow From Financing Activities, Continuing | $153.59M |
| Net Cash Flow | -$224.58M |
| Net Cash Flow, Continuing | -$224.58M |
| Comprehensive Income/Loss | -$161.00M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$161.00M |
| Other Comprehensive Income/Loss | $0.00 |